Table 4.
Base-case analysis for direct cost and effectiveness using Monte Carlo simulations of 100,000 hypothetical patients with moderate COPD
|
Direct cost ($) |
Effectiveness (exacerbation avoided/patient/year) |
|||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Strategy | Mean | (SD) | Minimum | Median | Maximum | Mean | (SD) | Minimum | Median | Maximum |
| No treatment | 392.1 | (134.74) | 304.405 | 384.405 | 972.995 | 0.69443 | (0.4376) | 0.18875 | 0.56625 | 1.85025 |
| Salmeterol | 1268.66 | (309.83) | 644.815 | 1325.64 | 1919.02 | 1.05156 | (0.51591) | 0.28313 | 0.84938 | 2.13338 |
| Tiotropium | 1408.59 | (311.79) | 696.295 | 1480.08 | 2073.46 | 1.12855 | (0.46041) | 0.33975 | 1.01925 | 2.30325 |
Abbreviation: SD, standard deviation.